Arvinas (ARVN) Cash from Operations Growth (3y) (2020 - 2026)
Arvinas (ARVN) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 34.32% |
| 10 | Arvinas | 531.20 Mn | -83.70 Mn | - | 8.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.79% |
| Dec 31, 2025 | 24.70% |
| Sep 30, 2025 | 3.90% |
| Jun 30, 2025 | -6.67% |
| Mar 31, 2025 | -15.90% |
| Dec 31, 2024 | -33.06% |
| Sep 30, 2024 | -29.82% |
| Jun 30, 2024 | 45.20% |
| Mar 31, 2024 | -35.72% |
| Dec 31, 2023 | -42.10% |
| Sep 30, 2023 | -55.89% |
| Jun 30, 2023 | -60.63% |
| Mar 31, 2023 | -75.23% |
| Dec 31, 2022 | -63.96% |
| Sep 30, 2022 | -235.99% |
| Jun 30, 2022 | -79.59% |
| Mar 31, 2022 | -64.91% |
| Dec 31, 2021 | -42.82% |
| Sep 30, 2021 | 300.06% |
| Jun 30, 2021 | -57.31% |